SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
LLY Analysis & Videos »
LLY: Bull or Bear?
Lilly's stock meanders, but remains a Buy
LLY
+14.55%
in
65 days
Filed under: Lilly (Eli) (LLY), Stocks to Buy  Eli Lilly & Co. (NYSE: LLY) stock has unexpectedly meandered since the June 8, 2009 Buy recommendation at a price of $34.10, but the aforementioned probably represents selected investor jitters about the likely, federal health care reform legislation.
Ignore those jitters. The major components of health care reform have not been determined as of September 30, 2009, but the pharma calculation remains the same as it was in June. The legislation will be net-positive for major pharmaceutical companies, under the thesis that there will be 30-45 million...
|
BioMedReports FDA Calendar: Seven Laggard Trades
LLY
|
|
|
+11.88%
in
171 days
Below are seven companies from the <font> BioMedReports.com FDA Calendar </font> database of over 200 entries, which have pending new drug decision(s) at the FDA combined with a stock price that is below its 200-day moving average (200-DMA). The list includes a balanced mix of two large-caps, two mid-caps, and three small-cap stocks which have been laggards in the overall market rally with looming regulatory catalysts in the form of FDA new drug decisions serving as potential upside catalysts. Data Source: Yahoo! Finance on 6/17/09 during late day trading. <> <font> <>http...
|
FDA, Clinical Trial Updates: GENZ, HGSI, LLY, NGSX
LLY
|
|
|
-3.44%
in
27 days
(closed on 06/17/09)
<> Below is a summary of updates to the <font> BioMedReports.com </font> database of over 200 entries included in the <font> FDA and Clinical Trial Calendars </font> . The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), and pending re-submissions...
|
Eli Lilly and Co (New York Stock Exchange)
LLY
|
|
|
+11.05%
in
229 days
http://www.lilly.com/ <> Eli Lilly and Company, incorporated in 1901, discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through owned or leased facilities in the United States, Puerto Rico and 25 other countries. Eli Lilly and Company’s products are sold in approximately 135 countries. The Company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. It<><><><><><><><><><><><><><>...
|
Updated FDA, Clinical Trial Calendars: CRME, MRK, LLY, PRX
LLY
|
|
|
+6.07%
in
41 days
(closed on 05/21/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 115 entries through 4/9/09. The FDA Calendar includes the following information: company name, ticker, decision ...
|
Updated Clinical Trial and FDA Decision Calendars
LLY
|
|
|
+15.74%
in
37 days
(closed on 04/10/09)
Posted by: Mike Havrilla in Untagged on Mar 04, 2009 <!-- Post Teaser Text --> <> Below are some recent updates to the BioMedReports.com -- FDA and Clinical Trial Calendars : <> 1.) Auxilium Pharma (AUXL): 3/2/09 BLA submission with priority review request for XIAFLEX (clostridial collagenase for injection), a novel, first-in-class, orphan-designated biologic for the treatment of Dupuytren's contracture. 5/2/09 is the date for FDA to accept the filing for review and decide on prior...
|
FDA Calendar: New Entries, One-Week Outlook
LLY
|
|
|
-26.00%
in
26 days
(closed on 03/04/09)
FDA Calendar: New Entries, One-Week Outlook The table at my website link below includes 84 pending FDA new product decision dates. Click here for a link to my previous calendars and here for 16 extreme FDA trades of companies with market caps below $150M with pending decisions. New Entries on the FDA Calendar: <> 1.) Acorda Therapeutics (ACOR): ACOR filed a NDA for Fampridine-SR Oral Tablet to improve the walking ability of people with multiple scleros...
|
FDA Calendar: Two Advisory Panel Meetings
LLY
|
|
|
+1.11%
in
3 days
(closed on 02/06/09)
FDA Calendar: Two Advisory Panel Meetings By Mike Havrilla on 2/3/09 ETF Innovators The tables at my website link below feature an updated calendar of 79 expected FDA new product decisions and 91 pending clinical trial result estimates + pending FDA re-submissions or new submissions for regulatory approval. Click here for a link to my previous calendars. <> 1.) Eli Lilly (LLY) and Daiichi Sanky (DSKYY) have a FDA advisory panel meeting today to review their potent...
|
Trading the Trials and FDA Decision Calendar
LLY
|
|
|
+0.11%
in
10 days
(closed on 02/03/09)
Trading the Trials and FDA Decision Calendar The tables at my website links below feature an updated calendar of 80 expected FDA new product decisions and 89 pending clinical trial result estimates + pending FDA re-submissions. Click here for a link to my previous FDA calendars and click here for a list of 14 extreme trades of companies with market caps below $100M and pending new drug decisions at the FDA. <> Below is a summary of the major updates on the calendar...
|
FDA Decision Date Calendar
LLY
|
|
|
-1.57%
in
11 days
(closed on 01/24/09)
<> 
<>
The accompanying table [click to enlarge] includes an updated calendar of expected FDA new product decisions with over 70 entries as a follow-up to my previous article on pending clinical trial results .
Click here for a link to my previous FDA calendars and the companies listed below have expected decisions within the next month or decisions which are overdue for a ruling by the agency.
1.) Schering-Plough (SGP): Saphris (asenapine) – nearly three months overdue
2.) Genzyme (GENZ): Synvis...
|
A Calendar of Expected Clinical Trial Results
LLY
|
|
|
-0.55%
in
2 days
(closed on 01/13/09)
<> 
The accompanying table [click to enlarge] includes 58 entries of expected clinical trial results in addition to pending FDA applications for new product approvals + a list of companies which will be required to re-submit their applications due to complete response letters from the agency.
See my recent article on 20 emerging healthcare stocks to watch in 2009 for more details on some of the companies included in the accompanying calendar, in addition to the following companies with near-term catalysts in...
|
Updated FDA Calendar
LLY
|
|
|
+10.45%
in
29 days
(closed on 01/11/09)
<> 
The accompanying table [click to enlarge] includes a weekly update of 71 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Decision Catalyst Index. Since my article last week , the following action has taken place at FDA:
1.) Pain Therapeutics (PTIE) & King Pharma (KG) lost 21% and 7%, respectively, today after receiving a complete response letter from the FDA for their abuse-resistant form of controlled-release oxycodone, which is designed to deter the abuse and diver...
|
FDA Calendar: A Weekly Update
LLY
|
|
|
-2.41%
in
7 days
(closed on 12/12/08)
<> 
The accompanying table [click to enlarge] presents an updated calendar of 73 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index. Below is a summary of the FDA action over the past week.
1.) ViroPharma (VPHM) – Filed a sBLA on 12/1/08 to expand use of Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema [HAE], which is already FDA approved for regular use in the prevention of angioedema attacks in adolescent and adult patients with HAE. Standa< />< />< />< /><>< />< />< />< />< />< />< />< /><>< />< />< />< /><>...
|
Stock Picks for Healthy Returns
LLY
|
|
|
+8.45%
in
10 days
(closed on 12/05/08)
<> Abbott Labs (ABT) is a consistent performer with diversified healthcare operations, including pharmaceuticals, diagnostics, medical nutrition products, and medical devices/stents. ABT is back to the lower end of its trading range near 50 bucks, presenting an excellent entry point with a 2.8% dividend yield and forward PE of about 14X.
Celgene (CELG) is also trading at the low end of its trading range around 50 bucks as a large-cap growth stock focused on cancer biotech products and research with an estimated PEG ratio below one.
...
|
A Backlog of Decisions is Building at the FDA
LLY
|
|
|
-3.32%
in
18 days
(closed on 11/25/08)
<> 
The accompanying table presents 70 FDA product approval decision dates along with the market caps and one year stock price change for the underlying companies. A note of caution for investors and traders is that the most common outcome from the FDA in the past year has been a delay in decisions due to understaffed conditions at the agency. However, several companies have pending decisions which are likely to occur either before year-end or early next year and will have a major impact on their stock prices.
Disco...
|
People Bullish on LLY
People Bearish on LLY
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
|
|
|
|
Andy
(+396.69% risk: conservative)
|
|
|
|
|
|
|
Andy
(+396.69% risk: conservative)
|
|
|
More Resources
|
About Eli Lilly and Company
- Answers.com
